Buy & Sell GSK plc (GSK) – GSK plc Price Today
Aura AI Summary
Key Stats
- $103.23BMarket Cap
- HealthSector
- -16.58%3M Drawdown
- $124.20BEnterprise Value
- 3.51%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 84 daysTypical Hold Time
GSK plc (GSK) is currently valued at a market capitalization of $103.23B, with an enterprise value of $124.20B. Over the past 52 weeks, GSK plc has traded between a low of $36.2 and a high of $61.18, highlighting its annual price range. Over the past three months, GSK plc has recorded a drawdown of -16.58%, reflecting recent price volatility. GSK plc offers a dividend yield of 3.51%, with the most recent dividend of $0.46 paid on 15 May 26. On average, investors hold GSK plc for approximately 84 days, indicating typical investor behavior on the platform.
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Most Recent News
Enhanced Games debuts in Las Vegas with boosted athletes and a TikTok-friendly sports format
Enhanced Games will hold its first competition in Las Vegas featuring 50 enhanced athletes, including Olympic and world champions, competing in a new sports format designed for digital and social media viewing. The event combines track, pool, and wei...

Phibro Animal Health CEO sold 21,120 shares worth $1.2 million
Phibro Animal Health's CEO recently sold 21,120 shares of the company, generating proceeds of approximately $1.2 million. This insider sale might indicate the CEO's personal financial planning or a strategic move, but it could also raise questions am...

Patient Square buys 210,000 shares of Nektar Pharmaceuticals, signaling strong confidence.
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
